NCT01466543

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity

Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.

Detailed description

Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral vessels and lead to an increase in cerebral blood flow. The main mechanism of subcortical vascular cognitive impairment are hypoperfusion of the brain. Therefore, in this study, the investigators will investigate whether Udenafil can increase cerebral blood flow and also lower peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.

Conditions

• Vascular Dementia
• Subcortical Vascular Dementia

Interventions

Type	Name	Description
DRUG	Zydena (Udenafil)	Zydena (Udenafil) 100 mg, one time
DRUG	Placebo	Placebo

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-03-01
• Completion: 2012-11-01
• First posted: 2011-11-08
• Last updated: 2011-11-08

Locations

1 site across 1 country: South Korea